After the chaotic year 2021, with several forecast reductions and a decline of the TeamViewer share of around 80%, the past fiscal year was characterized by consolidation, both in the operating business and on the stock exchange. By achieving its annual targets, the MDAX-listed company partially regained the confidence of investors and analysts. With a positive outlook, TeamViewer expects double-digit revenue growth within a range of 10% to 14% for fiscal year 2023. With stable profitability, the long-term rebound could gain further momentum. The planned exit from the horrendous shirt sponsorship deal with Manchester United should provide a significant positive effect.
The ramp-up of electromobility continued in 2022. Despite delays due to blown supply chains and plant closures caused by Corona lockdowns, sales of pure battery-powered vehicles increased by around 63% to 7 million. Globally, US manufacturer Tesla still holds the most market share, with 1.3 million units sold. In China, however, the world's largest market, the company of the controversial leader Elon Musk was already knocked off its throne in the first half of the year by the Chinese technology company BYD. Since then, the Warren Buffett-backed group has continued to expand its lead and is likely to come closer to its global place in the sun by expanding into other countries.
Scientific findings gain significance when validated and discussed by independent researchers. Defence Therapeutics' technology recently received funding and expert endorsement from Canadian biotech funder CQDM, which is funded by numerous industry multinationals, among others. We look at what the collaboration could mean for Defence Therapeutics, why nasal spray as chemotherapy is increasingly likely, and why Defence's technology portfolio fits the bill right now in what analysts expect to be a wave of acquisitions in the biotech sector.
The war in Ukraine exacerbates the need for the measures adopted in recent years to change our energy supply. The sudden scarcity and accompanying price explosion of fossil fuels is driven by our dependence on Russia and China alone in the European renewal process. Experts now realise that electromobility will probably only have a positive impact on the ambient air. Other concepts must be put on the table! When it comes to hydrogen, the EU can be said to be a global pioneer in hydrogen technology, despite much lip service. Nel ASA is a Scandinavian protagonist with high innovative power. An update from Norway.
Greentech is on everyone's lips. Politicians, climate activists and even ordinary citizens want a cleaner world and are establishing a more sustainable lifestyle. This can only be achieved through widely available and affordable energy because then industrial and mobility concepts can be transferred to an age of decarbonization. The clean forms of energy generation still require a high input of resources because the necessary infrastructure must first be created. In a second step, savings and a reduced CO2 footprint will follow. Globex Mining is a broadly diversified resource company; its founder and CEO, Jack Stoch, is a mining legend. He knows a thing or two about finding and industrially producing metals. Here is an update from Ontario.
Access to critical metals has always been a political issue. Strategic alliances are becoming increasingly crucial in geopolitical environments such as we have been experiencing since Donald Trump and Vladimir Putin. In a world where climate protection and armaments are being pushed in the same breath by all political forces, it is essential to secure access to raw materials. Tungsten has been placed on the EU's list of critical metals. Almonty Industries has been mining tungsten for a long time and is currently working on opening a mine in South Korea that can supply 5% of the world's supply. In addition, there is molybdenum there as well. We provide an update.
The significant corrections on the stock markets and the resulting drop in trading volumes dragged down the prices of online brokers in the past stock market year. Nevertheless, investors' appetite for shares remains unbroken despite the sharp price falls. Even in Germany, the land of savings books and growth certificates, the number of equity savers rose by 830,000 to 12.9 million in 2022, according to the German Equities Institute. Currently, the recovery on the stock markets is likely to continue as the phase of interest rate hikes comes to an end. This should also increase the trading figures again, whereby the segment of online brokers should experience a rebound. Smartbroker Holding AG, in particular, took a brutal blow due to delays in the development of the Next Generation Broker. If the new schedule is adhered to, there will be an attractive opportunity for disproportionate share price gains.
The market is gigantic for commercial vehicle manufacturers worldwide and represents an opportunity of the century. Due to the political requirements to drastically reduce greenhouse gas emissions in the transport sector over the next few years, the industry is currently experiencing a boom that is likely to continue well into the next decade. As of the end of 2021, around 93% of all light and heavy commercial vehicles in Germany were still powered by diesel, while the proportion of those using alternative fuels was a low 2%. In the course of tightening climate targets, this disparity should be turned around as quickly as possible in the next few years. First Hydrogen's vision is to become the leading designer and manufacturer of zero-emission, long-range hydrogen-powered commercial vehicles in the UK, EU and North America. By working with another industry heavyweight, the fledgling company is now moving ever closer to the mass market.
In January, a healthcare conference hosted by JP Morgan kissed the entire biotech industry awake. Another industry meeting is now scheduled for February in New York. Defence Therapeutics will be giving two presentations there to present itself to colleagues and investors. The Canadians will be presenting a flexible, patented platform technology and a whole series of projects that are about to enter Phase I trials. An mRNA vaccine candidate against skin cancer recently convinced with a cure rate of 60% in animals. We shed light on the Company and the share.
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make survival more likely for those affected. It is a matter of developing suitable active substances and launching modern therapies. Why some people get cancer, and others do not is unclear. The Munich-based biotechnology company is looking for suitable answers and is very far advanced with its current pipeline. Is the next blockbuster lurking here?